Total Payments
$132,735
2024 Payments
$35,145
Companies
5
Transactions
53
Medicare Patients
3,898
Medicare Billing
$284,008
Payment Breakdown by Category
Research$131,863 (99.3%)
Food & Beverage$872.83 (0.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $131,863 | 46 | 99.3% |
| Food and Beverage | $872.83 | 7 | 0.7% |
Payments by Type
Research
$131,863
46 transactions
General
$872.83
7 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Vanda Pharmaceuticals Inc. | $116,682 | 39 | $0 (2024) |
| Valeant Pharmaceuticals North America LLC | $15,363 | 8 | $0 (2017) |
| Almirall LLC | $418.14 | 4 | $0 (2024) |
| Galderma Laboratories, L.P. | $147.27 | 1 | $0 (2018) |
| Janssen Biotech, Inc. | $125.00 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $35,145 | 15 | Vanda Pharmaceuticals Inc. ($35,000) |
| 2023 | $47,500 | 16 | Vanda Pharmaceuticals Inc. ($47,500) |
| 2022 | $30,000 | 6 | Vanda Pharmaceuticals Inc. ($30,000) |
| 2021 | $4,123 | 3 | Vanda Pharmaceuticals Inc. ($4,000) |
| 2019 | $456.93 | 4 | Vanda Pharmaceuticals Inc. ($182.42) |
| 2018 | $147.27 | 1 | Galderma Laboratories, L.P. ($147.27) |
| 2017 | $15,363 | 8 | Valeant Pharmaceuticals North America LLC ($15,363) |
All Payment Transactions
53 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/26/2024 | Vanda Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $2,500.00 | Research |
| Study: AN OPEN LABEL STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF TRADIPITANT IN PARTICIPANTS AFFECTED BY MOTION SICKNESS | ||||||
| 10/29/2024 | Vanda Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $2,500.00 | Research |
| Study: AN OPEN LABEL STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF TRADIPITANT IN PARTICIPANTS AFFECTED BY MOTION SICKNESS | ||||||
| 10/08/2024 | Vanda Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $2,500.00 | Research |
| Study: AN OPEN LABEL STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF TRADIPITANT IN PARTICIPANTS AFFECTED BY MOTION SICKNESS | ||||||
| 09/18/2024 | Vanda Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $2,500.00 | Research |
| Study: A STUDY TO INVESTIGATE THE EFFICACY OF TRADIPITANT IN SUBJECTS AFFECTED BY MOTION SICKNESS | ||||||
| 09/18/2024 | Vanda Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $2,500.00 | Research |
| Study: AN OPEN LABEL STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF TRADIPITANT IN PARTICIPANTS AFFECTED BY MOTION SICKNESS | ||||||
| 07/30/2024 | Vanda Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $2,500.00 | Research |
| Study: AN OPEN LABEL STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF TRADIPITANT IN PARTICIPANTS AFFECTED BY MOTION SICKNESS | ||||||
| 05/22/2024 | Vanda Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $2,500.00 | Research |
| Study: A STUDY TO INVESTIGATE THE EFFICACY OF TRADIPITANT IN SUBJECTS AFFECTED BY MOTION SICKNESS | ||||||
| 05/15/2024 | Vanda Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $2,500.00 | Research |
| Study: AN OPEN LABEL STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF TRADIPITANT IN PARTICIPANTS AFFECTED BY MOTION SICKNESS | ||||||
| 05/15/2024 | Vanda Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $2,500.00 | Research |
| Study: A STUDY TO INVESTIGATE THE EFFICACY OF TRADIPITANT IN SUBJECTS AFFECTED BY MOTION SICKNESS | ||||||
| 04/03/2024 | Vanda Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $2,500.00 | Research |
| Study: AN OPEN LABEL STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF TRADIPITANT IN PARTICIPANTS AFFECTED BY MOTION SICKNESS | ||||||
| 03/20/2024 | Vanda Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $2,500.00 | Research |
| Study: AN OPEN LABEL STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF TRADIPITANT IN PARTICIPANTS AFFECTED BY MOTION SICKNESS | ||||||
| 03/20/2024 | Vanda Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $2,500.00 | Research |
| Study: AN OPEN LABEL STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF TRADIPITANT IN PARTICIPANTS AFFECTED BY MOTION SICKNESS | ||||||
| 03/20/2024 | Vanda Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $2,500.00 | Research |
| Study: AN OPEN LABEL STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF TRADIPITANT IN PARTICIPANTS AFFECTED BY MOTION SICKNESS | ||||||
| 03/20/2024 | Vanda Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $2,500.00 | Research |
| Study: A STUDY TO INVESTIGATE THE EFFICACY OF TRADIPITANT IN SUBJECTS AFFECTED BY MOTION SICKNESS | ||||||
| 03/10/2024 | Almirall LLC | Klisyri (Drug) | Food and Beverage | In-kind items and services | $145.34 | General |
| Category: Dermatology | ||||||
| 12/21/2023 | Vanda Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $2,500.00 | Research |
| Study: A STUDY TO INVESTIGATE THE EFFICACY OF TRADIPITANT IN SUBJECTS AFFECTED BY MOTION SICKNESS | ||||||
| 12/21/2023 | Vanda Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $2,500.00 | Research |
| Study: AN OPEN LABEL STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF TRADIPITANT IN PARTICIPANTS AFFECTED BY MOTION SICKNESS | ||||||
| 12/21/2023 | Vanda Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $2,500.00 | Research |
| Study: AN OPEN LABEL STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF TRADIPITANT IN PARTICIPANTS AFFECTED BY MOTION SICKNESS | ||||||
| 12/21/2023 | Vanda Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $2,500.00 | Research |
| Study: AN OPEN LABEL STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF TRADIPITANT IN PARTICIPANTS AFFECTED BY MOTION SICKNESS | ||||||
| 11/15/2023 | Vanda Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $2,500.00 | Research |
| Study: A STUDY TO INVESTIGATE THE EFFICACY OF TRADIPITANT IN SUBJECTS AFFECTED BY MOTION SICKNESS | ||||||
| 11/15/2023 | Vanda Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $2,500.00 | Research |
| Study: A STUDY TO INVESTIGATE THE EFFICACY OF TRADIPITANT IN SUBJECTS AFFECTED BY MOTION SICKNESS | ||||||
| 10/04/2023 | Vanda Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $2,500.00 | Research |
| Study: AN OPEN LABEL STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF TRADIPITANT IN PARTICIPANTS AFFECTED BY MOTION SICKNESS | ||||||
| 09/06/2023 | Vanda Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $2,500.00 | Research |
| Study: AN OPEN LABEL STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF TRADIPITANT IN PARTICIPANTS AFFECTED BY MOTION SICKNESS | ||||||
| 09/06/2023 | Vanda Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $2,500.00 | Research |
| Study: AN OPEN LABEL STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF TRADIPITANT IN PARTICIPANTS AFFECTED BY MOTION SICKNESS | ||||||
| 07/05/2023 | Vanda Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $2,500.00 | Research |
| Study: AN OPEN LABEL STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF TRADIPITANT IN PARTICIPANTS AFFECTED BY MOTION SICKNESS | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED STUDY INVESTIGATING THE EFFICACY OF TRADIPITANT IN TREATING MOTION SICKNESS | Vanda Pharmaceuticals Inc. | $51,500 | 12 |
| AN OPEN LABEL STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF TRADIPITANT IN PARTICIPANTS AFFECTED BY MOTION SICKNESS | Vanda Pharmaceuticals Inc. | $47,500 | 19 |
| A STUDY TO INVESTIGATE THE EFFICACY OF TRADIPITANT IN SUBJECTS AFFECTED BY MOTION SICKNESS | Vanda Pharmaceuticals Inc. | $17,500 | 7 |
| A Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2-Arm, Parallel Group Comparison Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris | Valeant Pharmaceuticals North America LLC | $15,363 | 8 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 1,003 | 1,480 | $180,115 | $72,816 |
| 2022 | 12 | 969 | 1,417 | $175,810 | $73,223 |
| 2021 | 10 | 1,027 | 1,475 | $174,575 | $76,118 |
| 2020 | 10 | 899 | 1,200 | $146,335 | $61,852 |
Total Patients
3,898
Total Services
5,572
Medicare Billing
$284,008
Procedure Codes
44
All Medicare Procedures & Services
44 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 464 | 678 | $64,410 | $28,717 | 44.6% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 139 | 179 | $30,430 | $14,217 | 46.7% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 119 | 147 | $21,315 | $7,101 | 33.3% |
| 12032 | Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | Office | 2023 | 21 | 22 | $8,470 | $6,075 | 71.7% |
| 11104 | Punch biopsy, first skin growth | Office | 2023 | 56 | 58 | $11,020 | $6,066 | 55.0% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 44 | 69 | $7,935 | $2,938 | 37.0% |
| 11603 | Removal of cancer skin growth of body, arms, or legs, 2.1-3.0 cm | Office | 2023 | 14 | 17 | $9,350 | $2,144 | 22.9% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2023 | 32 | 32 | $4,800 | $1,572 | 32.7% |
| 11602 | Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | Office | 2023 | 12 | 13 | $5,525 | $1,444 | 26.1% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 75 | 237 | $14,220 | $1,337 | 9.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 12 | 12 | $1,440 | $953.40 | 66.2% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 15 | 16 | $1,200 | $252.84 | 21.1% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 444 | 638 | $60,515 | $28,462 | 47.0% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 147 | 178 | $30,260 | $14,277 | 47.2% |
| 12032 | Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | Office | 2022 | 23 | 26 | $10,010 | $7,072 | 70.7% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 110 | 136 | $19,720 | $6,423 | 32.6% |
| 11104 | Punch biopsy, first skin growth | Office | 2022 | 51 | 54 | $10,260 | $5,762 | 56.2% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2022 | 40 | 74 | $8,510 | $3,186 | 37.4% |
| 11602 | Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | Office | 2022 | 18 | 21 | $8,925 | $2,429 | 27.2% |
| 11603 | Removal of cancer skin growth of body, arms, or legs, 2.1-3.0 cm | Office | 2022 | 12 | 13 | $7,150 | $1,672 | 23.4% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2022 | 29 | 29 | $4,350 | $1,301 | 29.9% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 62 | 214 | $12,840 | $1,245 | 9.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 16 | 16 | $1,920 | $1,052 | 54.8% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2022 | 17 | 18 | $1,350 | $342.00 | 25.3% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 462 | 626 | $59,470 | $28,698 | 48.3% |
About Dr. James Milbauer, MD
Dr. James Milbauer, MD is a Specialist healthcare provider based in Parsippany, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/10/2006. The National Provider Identifier (NPI) number assigned to this provider is 1598744450.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. James Milbauer, MD has received a total of $132,735 in payments from pharmaceutical and medical device companies, with $35,145 received in 2024. These payments were reported across 53 transactions from 5 companies. The most common payment nature is "" ($131,863).
As a Medicare-enrolled provider, Milbauer has provided services to 3,898 Medicare beneficiaries, totaling 5,572 services with total Medicare billing of $284,008. Data is available for 4 years (2020–2023), covering 44 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Location Parsippany, NJ
- Active Since 01/10/2006
- Last Updated 07/08/2007
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1598744450
Products in Payments
- Klisyri (Drug) $145.34
- Tremfya (Drug) $125.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.